ZTS
USDZoetis Inc. Class A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$120.430
Kõrge
$121.310
Madal
$118.520
Maht
8.35M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
52.8B
Tööstusharu
Drug Manufacturers - Specialty & Generic
Riik
United States
Kauplemisstatistika
Keskmine maht
3.12M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
Morgan Stanley analyst Erin Wright maintains Zoetis with a Overweight and lowers the price target from $211 to $175.
Zoetis Stock Outlook Clouded By Rising Competitive Pressures
Zoetis tops Q3 earnings estimates but trims 2025 sales forecast as companion animal growth slows and competition weighs on its outlook.
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing
Zoetis Appoints Stephanie Tilenius to its Board of Directors
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as
Seotud aktsiad
CVKD
Cadrenal Therapeutics Inc.
SUPV
Grupo Supervielle S.A. American Depositary Shares each Representing five shares
GIS
General Mills
RLTY
Cohen & Steers Real Estate Opportunities and Income Fund Common Shares of Beneficial Interest
CYTO
Altamira Therapeutics Ltd. Common Shares
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.